home page home page|
PubMed list |
Paper inaccessible? |
2024
Heimesaat MM, Mousavi S, Lobo de Sá FD, Peh E, Schulzke JD, Bücker R, Kittler S, Bereswill S (2024) Oral curcumin ameliorates acute murine campylobacteriosis. Front. Immunol. 15: 1363457 (14 pages). doi: 10.3389/fimmu.2024.1363457 (°IF 5.7)
2022
Kaak JL, Lobo de Sá FD, Turner JR, Schulzke JD, Bücker R (2022) Unraveling the intestinal epithelial barrier in cyanotoxin microcystin-treated Caco-2 cell monolayers. Ann. NY Acad. Sci. 1516(1): 188-196, doi: 10.1111/nyas.14870 (IF 5.2)
2021
Lobo de Sá FD, Backert S, Nattramilarasu PK, Mousavi S, Sandle GI, Bereswill S, Heimesaat MM, Schulzke JD, Bücker R (2021) Vitamin D reverses disruption of gut epithelial barrier function caused by Campylobacter jejuni.
Lobo de Sá FD, Heimesaat MM, Bereswill S, Nattramilarasu PK, Schulzke JD, Bücker R (2021) Resveratrol prevents Campylobacter jejuni-induced leaky gut by restoring occludin and claudin-5 in the paracellular leak pathway. Front. Pharmacol. 12: 640572. doi: 10.3389/fphar.2021.640572 (IF 6.0)
Lobo de Sá FD, Schulzke JD, Bücker R (2021) Diarrheal mechanisms and the role of intestinal barrier dysfunction in Campylobacter infections. Curr. Top. Microbiol. Immunol. 431: 203-231. doi: 10.1007/978-3-030-65481-8_8 (IF 4.7)
Nattramilarasu PK, Lobo de Sá FD, Schulzke JD, Bücker R (2021) Immune-mediated aggravation of the Campylobacter concisus-induced epithelial barrier dysfunction. Int. J. Mol. Sci. 22(4): 2043 (23 pages). doi: 10.3390/ijms22042043, Supplement PDF (IF 6.2)
2020
Heimesaat MM, Mousavi S, Escher U, Lobo de Sá FD, Peh E, Schulzke JD, Kittler S, Bücker R, Bereswill S (2020) Resveratrol alleviates acute Campylobacter jejuni-induced enterocolitis in a preclinical murine intervention study. Microorganisms 8: 1858 (15 pages) [PubMed] [DOI] [PDF] [Supplement] (IF 4.1)
Butkevych E, Lobo De Sá FD, Nattramilarasu PK, Bücker R (2020) Contribution of epithelial apoptosis and subepithelial immune responses in Campylobacter jejuni-induced barrier disruption Front. Microbiol. 11: 344 (14 pages) [PubMed] [WebPage] [PDF] (IF 5.6)
Nattramilarasu PK, Bücker R, Lobo de Sá FD, Fromm A, Nagel O, Lee IM, Butkevych E, Mousavi S, Genger C, Kløve S, Heimesaat MM, Bereswill S, Schweiger MR, Nielsen HL, Troeger H, Schulzke JD (2020) Campylobacter concisus impairs sodium absorption in colonic epithelium via ENaC dysfunction and claudin-8 disruption. Int. J. Mol. Sci. 21(2): e373 (23 pages) [PubMed] [WebPage] [PDF] [Supplements] (IF 5.9)
2019
Lobo de Sá FD, Butkevych E, Nattramilarasu PK, Fromm A, Mousavi S, Moos V, Golz JC, Stingl K, Kittler S, Seinige D, Kehrenberg C, Heimesaat MM, Bereswill S, Schulzke JD*, Bücker R (*corresponding) (2019) Curcumin mitigates immune-induced epithelial barrier dysfunction by Campylobacter jejuni. Int. J. Mol. Sci. 20(19): 4830 (19 pages) [PDF] [WebPage] [PDF] (IF 4.6)
Mousavi S, Lobo de Sá FD, Schulzke JD, Bücker R, Bereswill S, Heimesaat MM (2019) Vitamin D in acute campylobacteriosis ‒ results from an intervention study applying a clinical Campylobacter jejuni induced enterocolitis model. Front. Immunol. 10: 2094 (14 pages) [PubMed] [WebPage] [PDF] (IF 5.1)
Theses
Lobo de Sá F (2017) Establishment of an in vitro assay for the testing of new compounds and their antifibrotic potential for the search of drugs for the treatment of liver fibrosis. Master Thesis
Lobo de Sá F (2014) Investigations of the microbial and enzymatic cAMPsynthesis. Bachelor Thesis
